GET THE APP
Enteric-Coated Mycophenolate Sodium and Gastrointestinal Prophylaxis in Renal Transplant Patients | Abstract
AgiAl Publishing House

The Open Access Journal of Science and Technology

Abstract

About the Journal Abstracting and Indexing Aim and Scope Author Guidelines Article Processing Charges Articles in Process Contact Information Disclosure Policy and Publication Ethics Editorial Board Editorial Workflow Archive
Google Scholar citation report
Citations : 409

The Open Access Journal of Science and Technology received 409 citations as per Google Scholar report

Flyer image
Indexed In
  • Genamics JournalSeek
  • Directory of Open Access Journals
  • Pollution Abstracts
  • Publons
  • International committee of medical journals editors (ICMJE)
  • Google Scholar
  • Chemical Abstract
View More
Awards Nomination

Enteric-Coated Mycophenolate Sodium and Gastrointestinal Prophylaxis in Renal Transplant Patients

Author(s): Karen Parker ,Winifred Bryant, Connie Garris-Sutton,Fatima Rana ,and Paul Bolin

Background: The purpose of this study was to evaluate the discontinuation or reduction of gastrointestinal (GI) comedicationuseandsubjects’subsequentGIsymptomsandpsychologicalwell-beingafterconversionfrommycophenolatesodium (MMF) to enteric-coated mycophenolate sodium (EC-MPS). Study Design: Prospective, single-center, open label, longitudinal study.SettingsandParticipants:54renaltransplantsubjectswhoweresuccessfullyconvertedfromMMFtoEC-MPSpreviously duetoGIsymptoms.Intervention:SubjectswereaskedtoreduceordiscontinuetheirGIco-medicationinaprogrammedfashion overathreemonthperiod.Subjectsweresubsequentlyfollowedforoneyear.Outcomes:PatientreporteduseofGImedications, symptoms,complaints,andoverallqualityoflife. Measurements:Assessmentswereperformedusingvalidatedpatient-reported outcome instruments. Cost savings was also measured. Results: Successful discontinuation or reduction of GI co-medication was achieved in 78% patients after 30 days and maintained through day 90. No significant changes in GI symptom assessments wereobservedfrombaselinetoday30or90despitediscontinuationorreductioninGIco-medication.Twelvemonthfollowup demonstratedsustainedimprovementin91%ofthesepatients.Annualcostsavingsperpatientafterreductionordiscontinuation of GI medication were estimated to be $925-$1850 for H-2 blockers and $1861-$3722 for proton-pump inhibitors. Limitations: Resultswerebasedonasinglecenter,openlabelexperienceandreliedonpatientreporteddata.Conclusions:Thisstudysupports successful long-term minimization of GI co-medications in maintenance renal transplant patients after conversion to EC-MPS. DatasuggestthatafterconversiontoEC-MPSrenaltransplantpatientscansuccessfullyreduceordiscontinueGIco-medication whilemaintainingtheirhealth-relatedqualityoflifeandoverallwell-being.

<

Share this article